---
title: "ABT: Solid revenue growth"
canonical_url: https://www.stockexpertai.com/journal/2025-12-17/abt-balance-sheet-q4-2025
last_updated: 2025-12-17T23:22:51.451Z
section: "Balance Sheet Intelligence"
author: "Charlie Bennett"
publisher: Stock Expert AI
tickers: ABT
content_type: journal-article
---

# ABT: Solid revenue growth

## The Take
- ABT's balance sheet shows strength with a health score of 80/100. Key strengths include strong fundamentals that support a positive outlook.

_Revenue growing at 6.9% YoY_

# Abbott Laboratories (ABT): A Steady Healthcare Performer in 2025

## Executive Summary

Abbott Laboratories is demonstrating robust financial health in a challenging healthcare market. With **$43.11B** in trailing twelve-month revenue and a strong **32.4%** profit margin, the company shows resilience and consistent growth. The **+6.9%** revenue expansion signals a positive trajectory in the medical technology and diagnostics sector.

## Profitability & Growth

Abbott's financial performance tells a story of steady expansion. Revenue grew by a solid **6.9%** year-over-year, indicating the company is successfully navigating market complexities. The **32.4%** profit margin is particularly impressive, showcasing operational efficiency that outpaces many competitors in the healthcare space.

Key profitability highlights:
- Net Income (TTM): **$13.98B**
- Earnings Per Share (TTM): **$3.95**
- Operating Margin: **19.39%**

So what? These metrics reveal Abbott isn't just growing, but growing smartly—maximizing every dollar of revenue into sustainable profit.

## Financial Health

The balance sheet paints a picture of financial stability:
- Total Assets: **$74.36B**
- Total Liabilities: **$34.33B**
- Stockholder Equity: **$39.80B**

The **32.2%** debt-to-equity ratio demonstrates conservative financial management. With **$7.8B** in cash, Abbott maintains a strong liquidity position to weather economic uncertainties.

## Cash Flow & Dividends

Cash flow metrics underscore the company's financial strength:
- Operating Cash Flow (TTM): **$9.04B**
- Free Cash Flow (TTM): **$6.78B**
- Dividend Yield: **1.99%**

The robust free cash flow suggests Abbott can comfortably fund operations, invest in R&D, and return value to shareholders through dividends.

## Valuation & Forecast

Valuation metrics reveal an attractively priced healthcare performer:
- P/E Ratio (TTM): **15.94**
- Price/Sales: **5.03**
- Revenue Forecast (Next Year): **$48.22B**

Analyst estimates point to continued growth, with EPS expected to rise from **$5.15** to **$5.68** in the next year.

## Verdict

**Bull Case**: Strong margins, consistent growth, and robust cash flow position Abbott as a resilient healthcare investment.

**Bear Case**: Potential market saturation and competitive pressures could challenge future expansion.

**Balanced Perspective**: Abbott demonstrates financial discipline and steady growth, making it an attractive option for investors seeking stability in the healthcare sector.

Confidence Level: 85% based on current financial indicators and consistent performance.

## Key Strengths
- Solid revenue growth
- High profit margins
- Low debt levels

## Related Tickers
- [ABT](https://www.stockexpertai.com/stock/abt)

---
_AI-generated under human editorial supervision. Educational research, not financial advice._